Plain-English translation of NCT05373758 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
When people with HIV take tenofovir, lamivudine, and dolutegravir (TLD) for at least a year, their viral load—the amount of virus in their blood—should become undetectable. But for some people, the virus starts multiplying again despite taking the medication regularly. This trial tests three different strategies to help: using genetic testing to guide treatment changes, using genetic testing plus checking medication levels in urine, or switching immediately to a different class of medication.
Even with good medication adherence, some people's HIV can become resistant to their current treatment. Doctors in Uganda and South Africa need better guidance on how to quickly and effectively manage this situation to prevent the virus from getting stronger and keep people healthy.
You likely qualify if…
You likely don't qualify if…
If you join, you'll be randomly assigned to one of three groups that each use a different approach to manage your HIV treatment. You'll have study visits at enrollment (when you start), at week 24, and at week 48 (one year). At these visits, you'll have blood tests to measure your viral load, and depending on which group you're in, you may also have genetic testing of your virus or urine tests to check how much of the medication is in your body. The study lasts one year total.
AI-generated summary from trial data · Jun 23, 2026 · Not medical advice
South Africa
Uganda